XTL Biopharmaceuticals Ltd. – NASDAQ:XTLB
XTL Biopharmaceuticals Ltd. stock price today
XTL Biopharmaceuticals Ltd. stock price monthly change
XTL Biopharmaceuticals Ltd. stock price quarterly change
XTL Biopharmaceuticals Ltd. stock price yearly change
XTL Biopharmaceuticals Ltd. key metrics
Market Cap | 17.33M |
Enterprise value | N/A |
P/E | -5.9 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 1.42 |
PEG ratio | -0.03 |
EPS | -0.06 |
Revenue | N/A |
EBITDA | 353K |
Income | -378K |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeXTL Biopharmaceuticals Ltd. stock price history
XTL Biopharmaceuticals Ltd. stock forecast
XTL Biopharmaceuticals Ltd. financial statements
| Jun 2023 | 0 | -364K | |
|---|---|---|---|
| Sep 2023 | 0 | -215K | |
| Dec 2023 | 0 | -284K | |
| Mar 2024 | 0 | 485K |
| 2022-11-29 | -0.15 | -0.15 |
|---|---|---|
| 2023-03-22 | -0.14 | -0.14 |
| Jun 2023 | 2881000 | 163K | 5.66% |
|---|---|---|---|
| Sep 2023 | 2663000 | 162K | 6.08% |
| Dec 2023 | 2426000 | 206K | 8.49% |
| Mar 2024 | 2928000 | 223K | 7.62% |
| Jun 2023 | 0 | 0 | 0 |
|---|---|---|---|
| Sep 2023 | 0 | 0 | 0 |
| Dec 2023 | 0 | 0 | 0 |
| Mar 2024 | 0 | 0 | 0 |
XTL Biopharmaceuticals Ltd. alternative data
| Feb 2024 | 8 |
|---|---|
| Mar 2024 | 8 |
| Apr 2024 | 8 |
| May 2024 | 8 |
| Jun 2024 | 8 |
| Jul 2024 | 8 |
XTL Biopharmaceuticals Ltd. other data
| Period | Buy | Sel |
|---|---|---|
| Dec 2007 | 2250000 | 0 |
| Jan 2008 | 11259060 | 0 |
| Feb 2008 | 4632180 | 0 |
| Mar 2008 | 6423160 | 0 |
| Apr 2008 | 758610 | 0 |
| May 2008 | 155000 | 0 |
| Jun 2008 | 910330 | 0 |
| Nov 2008 | 0 | 40050370 |
| Patent |
|---|
Application PHARMACEUTICAL COMPOSITIONS COMPRISING 0.25 MG DOSE OF SYNTHETIC HUMAN PEPTIDES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS Filling date: 16 Jul 2020 Issue date: 29 Oct 2020 |
Wednesday, 14 August 2024 | ||
| XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million | globenewswire.com | |
Wednesday, 5 June 2024 | ||
| XTL Entered Definitive Agreement to Acquire The Social Proxy | globenewswire.com | |
Wednesday, 20 March 2024 | ||
| XTL To Aquire The Social Proxy | globenewswire.com | |
Monday, 20 September 2021 | ||
| Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual Meeting | PRNewsWire |
-
What's the price of XTL Biopharmaceuticals Ltd. stock today?
One share of XTL Biopharmaceuticals Ltd. stock can currently be purchased for approximately $1.32.
-
When is XTL Biopharmaceuticals Ltd.'s next earnings date?
Unfortunately, XTL Biopharmaceuticals Ltd.'s (XTLB) next earnings date is currently unknown.
-
Does XTL Biopharmaceuticals Ltd. pay dividends?
No, XTL Biopharmaceuticals Ltd. does not pay dividends.
-
How much money does XTL Biopharmaceuticals Ltd. make?
XTL Biopharmaceuticals Ltd. has a market capitalization of 17.33M. XTL Biopharmaceuticals Ltd. made a loss 1.78K US dollars in net income (profit) last year or -$0.14 on an earnings per share basis.
-
What is XTL Biopharmaceuticals Ltd.'s stock symbol?
XTL Biopharmaceuticals Ltd. is traded on the NASDAQ under the ticker symbol "XTLB".
-
What is XTL Biopharmaceuticals Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of XTL Biopharmaceuticals Ltd.?
Shares of XTL Biopharmaceuticals Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does XTL Biopharmaceuticals Ltd. have?
As Jul 2024, XTL Biopharmaceuticals Ltd. employs 8 workers.
-
When XTL Biopharmaceuticals Ltd. went public?
XTL Biopharmaceuticals Ltd. is publicly traded company for more then 20 years since IPO on 1 Sep 2005.
-
What is XTL Biopharmaceuticals Ltd.'s official website?
The official website for XTL Biopharmaceuticals Ltd. is xtlbio.com.
-
How can i contact XTL Biopharmaceuticals Ltd.?
XTL Biopharmaceuticals Ltd. can be reached via phone at +972 3 611 6600.
XTL Biopharmaceuticals Ltd. company profile:
XTL Biopharmaceuticals Ltd.
xtlbio.comNASDAQ
8
Biotechnology
Healthcare
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Ramat Gan, 5218102
CIK: 0001023549
ISIN: US98386D3070
CUSIP: 98386D307
